세계의 T세포 면역요법 시장 - 예측(2025-2030년)

T-Cell Immunotherapy Market is projected to reach USD 10.723 billion by 2030 from USD 6.277 billion in 2025, with a 11.30% CAGR.

The T-cell immunotherapy market is undergoing a significant transition, moving engineered autologous products, principally CAR-T and TCR-based therapies, from niche salvage treatments toward earlier lines of oncology care. This evolution is characterized by a shift in market bottlenecks away from initial clinical proof-of-concept and toward the challenges of reliable, timely production and securing consistent payer access. The market's trajectory is now directly shaped by discrete regulatory actions, strategic capacity investments, and continuous manufacturing process improvements, which collectively alter demand dynamics for clinical centers, manufacturers, and service providers.

Market Growth Drivers

A primary driver of market expansion is the continued regulatory approval of new indications. These approvals systematically increase the count of eligible patients, converting previously unmet medical needs into commercially addressable cohorts. Notably, approvals for TCR-based therapies in solid tumors have opened new segments of oncology, generating immediate and sustained demand for associated manufacturing slots, companion diagnostics, and specialized infusion capacity.

The scaling of commercial manufacturing represents another critical growth driver. Strategic capacity reservation and supply agreements are essential for converting latent clinical demand into executable treatments. These agreements directly unlock patient throughput, which in turn increases demand for peripheral services across the treatment journey, including apheresis scheduling, logistics, and necessary inpatient care.

Furthermore, ongoing process improvements that shorten the manufacturing turnaround time (TAT) are having a direct and positive impact on conversion rates. A reduced TAT increases the fraction of referred patients who remain clinically eligible for infusion at the time of product delivery. This operational efficiency directly raises the conversion of patient referrals into successfully treated individuals, maximizing the utility of existing manufacturing and clinical capacity.

Market Challenges and Strategic Opportunities

The market faces several significant constraints. A persistent manufacturing capacity mismatch, driven by limitations in clean-room availability, viral vector supply, and the inherent complexity of autologous workflows, caps the number of concurrent treatments that can be administered. This suppresses realized demand when expected turnaround times exceed the clinical windows of opportunity for patients.

Additionally, the management of unique toxicities such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) requires specialized inpatient resources. Treatment centers lacking these advanced capabilities must refer patients to specialized hubs, which geographically concentrates demand and can create access disparities.

These challenges are counterbalanced by substantial opportunities. The accumulation of real-world and clinical data supporting the use of T-cell therapies in earlier lines of treatment is making a significantly larger patient population eligible. This is coupled with increasing payer acceptance for earlier use, which raises demand per patient incidence. Another opportunity lies in regulatory shifts that enable outpatient administration, which can materially increase latent regional demand by allowing a broader range of hospitals to deliver these complex therapies.

Supply Chain and Regulatory Landscape

The T-cell immunotherapy supply chain is a multi-node, global operation. Autologous products require localized leukapheresis, controlled regional logistics to centralized manufacturing hubs, and final return shipment to the infusion center. Key production hubs remain concentrated in North America and selected EMEA locations. Within this chain, logistical complexity and fill/finish scheduling are recurring bottlenecks; strategic capacity agreements and process improvements directly relieve these constraints, enabling higher realized demand.

The regulatory environment is a key market shaper. In the United States, the FDA's accelerated approval pathways enable rapid market entry while often conditioning continued indication on confirmatory trial outcomes. This increases near-term demand but places a strong emphasis on post-market evidence generation for sustained uptake. In the European Union, the centralized ATMP (Advanced Therapy Medicinal Product) authorization provides single market access but requires detailed manufacturing comparability data. In China, local approvals and the growth of domestic manufacturing capability are increasingly influencing regional demand by reducing dependence on cross-border logistics.

In-Depth Segment Analysis

The segment for TCR (T-cell receptor) therapies is of particular importance as it opens segments of solid-tumor oncology previously inaccessible to CAR-T constructs. By targeting intracellular antigens presented on HLA molecules, TCR therapies have created commercially addressable cohorts for specific solid tumors. Demand in this segment is driven by diagnostic screening rates, the prevalence of HLA-eligible patients, and payer acceptance of high-cost, single-dose therapies. The commercial success of these products often involves post-market confirmatory requirements, which can front-load initial demand; sustained uptake is dependent on the demonstration of durable clinical benefit.

Hospitals and specialized treatment centers act as the primary demand gatekeepers. Their capacity-defined by the availability of trained staff, critical-care resources, and seamless logistical integration with apheresis and manufacturing providers-directly governs the conversion of referral volume into treated patients. Investments in dedicated cell therapy units and the development of outpatient infusion protocols are critical for increasing throughput, which in turn drives local market demand for manufacturing slots and supportive services.

Competitive Environment

The competitive landscape is defined by major pharmaceutical and biotechnology companies, each with distinct strategic focuses. Adaptimmune has positioned itself as a first mover in TCR commercialization, with a strategic emphasis on diagnostics-enabled targeting and expanding its solid-tumor pipeline. Gilead/Kite focuses on manufacturing scale and network optimization, leveraging regulatory process optimizations to shorten TAT and drive earlier-line adoption. Bristol Myers Squibb utilizes vertical integration across its portfolio and engages in strategic manufacturing partnerships to secure supply and broaden patient access. The market is characterized by a preference for players with robust manufacturing capabilities, regulatory expertise, and the ability to navigate complex reimbursement landscapes.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

• T-CELL IMMUNOTHERAPY MARKET BY TYPE
• Chimeric antigen receptor (CAR)
• T-cell receptor (TCR)
• Tumor-infiltrating lymphocyte (TIL)
• T-CELL IMMUNOTHERAPY MARKET BY INDICATION
• Melanoma
• Leukemia
• Ovarian cancer
• Others
• T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. T-CELL IMMUNOTHERAPY MARKET BY TYPE

• 5.1. Introduction
• 5.2. Chimeric antigen receptor (CAR)
• 5.3. T-cell receptor (TCR)
• 5.4. Tumor-infiltrating lymphocyte (TIL)

6. T-CELL IMMUNOTHERAPY MARKET BY INDICATION

• 6.1. Introduction
• 6.2. Melanoma
• 6.3. Leukemia
• 6.4. Ovarian cancer
• 6.5. Others

7. T-CELL IMMUNOTHERAPY MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. United Kingdom
  • 7.4.4. Spain
  • 7.4.5. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. India
  • 7.6.3. Japan
  • 7.6.4. South Korea
  • 7.6.5. Indonesia
  • 7.6.6. Thailand
  • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Cellular Biomedicine Group
• 9.2. Autolus Novartis
• 9.3. Gilead Sciences, Inc.
• 9.4. Adaptimmune Therapeutics
• 9.5. Cellectis
• 9.6. Bluebird bio
• 9.7. Immunocore
• 9.8. Innovative Cellular Therapeutics
• 9.9. Iovance Biotherapeutics
• 9.10. Celgene

10. APPENDIX

• 10.1. Currency
• 10.2. Assumptions
• 10.3. Base and Forecast Years Timeline
• 10.4. Key Benefits for the Stakeholders
• 10.5. Research Methodology
• 10.6. Abbreviations